Jiangsu Hengrui Pharmaceuticals Co.,Ltd (SHA:600276)

Market Cap	372.15B +28.7%
Revenue (ttm)	31.63B +13.0%
Net Income	7.71B +21.7%
EPS	1.18 +18.0%
Shares Out	6.62B
PE Ratio	47.56
Forward PE	39.82
Dividend	0.20 (0.35%)
Ex-Dividend Date	May 23, 2025

Volume	646,523
Average Volume	50,663,207
Open	57.01
Previous Close	56.38
Day's Range	56.12 - 57.01
52-Week Range	45.86 - 74.04
Beta	0.21
RSI	51.80
Earnings Date	Mar 25, 2026

About SHA:600276

Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1970
• Employees: 20,602
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600276

Financial Performance

In 2025, SHA:600276's revenue was 31.63 billion, an increase of 13.02% compared to the previous year's 27.98 billion. Earnings were 7.71 billion, an increase of 21.69%.